© All rights reserved
We grow innovation
HAPA medical partners with Australian Zelda Therapeutics for the advancement of clinical cannabinoid research
While experimental studies have already unveiled many mechanisms of action for a wide array of cannabinoids, there is still a lack of proper clinical trials which hinders the practical therapeutic application of cannabinoid medicine. Our partner Zelda Therapeutics brings together some of the world’s leading researchers and clinicians active in the study and use of medicinal cannabis for various indications. Our mutual effort aims to define the most relevant cannabinoid and terpene profile formulations to treat specific indications.
To this date, a phase I, open label study will evaluate the safety, tolerability, and pharmacokinetics of our medicinal cannabinoid oil formulations in chronic non-cancer pain patients („Opioid reduction trial“). A three year study will research the effects in a large cohort of terminal cancer patients targeting nausea, appetite and pain management. Furthermore, an insomnia and an autism trial is currently in progress.
HAPA pharm is actively responding to the situation of coronavirus (COVID-19) by following the recommendations